Drugs / Soberana Plus
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05689177 | Dec 2022 → Mar 2023 | — | Gomel State Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Soberana Plus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05689177 ↗ |
| Known as | FINLAY-FR-1A | “Protein subunit vaccine Soberana Plus (FINLAY-FR-1A) is a vaccine against COVID-19 produced by The Finlay Vaccine Institute and The Centre of Molecular Immunology (Republic of Cuba)” NCT05689177 ↗ |
| Modality | Vaccine | “is a vaccine against COVID-19” NCT05689177 ↗ |